North America Haemostatic Agents Market

North America Haemostatic Agents Market Size (2023 to 2028)

The size of the Haemostatic Agents Market in North America is predicted to hike at a prominent CAGR from 2023 to 2028.

Factors that drive the North American haemostatic agent market are the increasing incidence of bleeding during surgery and the growing emphasis on blood management. Additionally, innovations in surgical procedures, such as robot-assisted surgery and the ever-increasing geriatric population, are expected to drive demand in the North American market for haemostatic agents. The increasing number of patients with bleeding disorders requires the adoption of highly advanced haemostatic products. Besides, the prevalence of chronic diseases among the growing geriatric population increases the demand for haemostatic agents. There will be a high demand for haemostatic agents due to the increase in surgeries in the region, which will drive the growth of the haemostatic agents market. According to the World Health Organization (WHO), more than 1.55 million people die in traffic crashes worldwide. Numerous injuries resulting in severe bleeding contribute to the growth of the haemostatic agents market in the trend to go up.

However, the cost of the surgical procedures involved may limit the market's growth during the forecast period.

This research report on the North America Haemostatic Agents Market has been segmented and sub-segmented into the following categories:

• By Type: Thrombin Based Haemostats, Gelatin Based Haemostats, Collagen Based Haemostats, Oxidized Regenerated Cellulose Based Haemostats, Combination Haemostats, Fibrin Sealants, and Others
• By Treatment: Cardiovascular, General Surgery, Digestive Surgery, Neurosurgery, and Others    
• By End User: Hospitals, Surgery Centres, Nursing Homes, and Others    
• By Country: The United States, Canada, and Rest of North America

Regionally, the North American market has the largest market share globally despite having a low growth rate in recent years. It is expected as the scope for development in the region is relatively low. The entrant of new players into the market is not encouraged by the presence of significant market players native to the area.

The North American market is primarily fueled by the rapid increase in the geriatric population, the increasing number of surgeries, and the growing patient population. Besides, a growing number of players and products, along with a strong emphasis on research and development, is a key market driver in the U.S. The market in Asia-Pacific is expected to expand at a CAGR prominent during the forecast period. The increasing population, the initiatives are taken by governments in the field of health, and the increase in research and development activities are key factors in the market. In 2020, according to the CDC, in the United States, about 710,217 people die from heart disease each year, which represents 1 in 5 deaths, and coronary heart disease (CHD) is considered the most common type of heart disease, killing 421,913 people per year. According to research conducted by the American College of Obstetricians and Gynecologists, the rate of postpartum hemorrhage has increased by about 26.7% over the past decade in the United States. It will likely fuel the demand for hemostatic agents for surgery and other purposes.

Companies dominating the North America Haemostatic Agents Market profiled in this report are Ethicon, Pfizer, Baxter International, R. Bard, The Medicines Company, Anika Therapeutics, Advanced Medical Solutions, Integra LifeSciences, B Braun Melsungen, Gelita Medical, Equimedical, Vascular Solutions, Marine Polymer Technologies, and Z-Medica.